Company: PIII
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0001140361-25-014596
Chunk: 39

Company: P3 Health Partners Inc.
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 39
---
                        | ​ | 469,231 | ​ |  50,000 | ​ | 1,567,500 | ​ |         — |   |  ​112,500 | ​ |          5,054 | ​ |   ​2,204,285 |   |            |

| (1) | Amount for 2024 reflects a $35,000 spot bonus paid to Mr. Kavthekar in July 2024.  Amount for 2023 reflects a $50,000 signing bonus that was paid to Mr. Kavthekar on the six-month anniversary of his start 
 date.                                                                                                                                                                                                        |

| (2) | Amounts reflect the grant date fair value of the RSU awards granted to the named executive officers, as computed in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards                                       
 Codification (“ASC”) Topic 718, but excluding any impact of estimated forfeiture rates as required by SEC regulations, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions 
 used to calculate the value of all equity awards granted to executives in 2024 in Note 15 to the consolidated financial statements included in our 2024 Form 10-K. With respect to Drs. Abdou and Bacchus, amounts in 2023 represent the     
 incremental additional value of a grant of fully-vested restricted stock units (“RSUs”) that were granted in satisfaction of the second installment of transaction bonuses described in their transaction bonus agreements dated May 2022.   |

| (3) | Amounts reflect the grant date fair value of the option awards granted to the named executive officers, as computed in accordance with FASB ASC Topic 718, but excluding any impact of estimated forfeiture                                   
 rates as required by SEC regulations, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all equity awards granted to executives in 2024 in 
 Note 15 to the consolidated financial statements included in our 2024 Form 10-K.                                                                                                                                                              |

| (4) | Amounts represent bonuses earned by our NEOs under our annual bonus program. Please see the description of the annual bonus program under “2024 Bonuses” below. |

| (5) | In 2024, Dr. Coffman received cellphone reimbursement of $589; Dr. Abdou received severance pay of $1,046,154; Mr. Pedersen